Hormone therapy use and breast cancer incidence by histological subtypes in Sweden and Norway

Breast Journal

Volumn 18, Issue 6, 2012, Pages 549-556

  Suhrke, Pål ^a   Mæhlen, Jan ^a,b   Zahl, Per Henrik ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

breast cancer; epidemiology; hormone replacement therapy; invasive ductal carcinoma; invasive lobular carcinoma; mammography; postmenopausal hormone therapy

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; DRUG USE; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NORWAY; SWEDEN;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NORWAY; REGISTRIES; SWEDEN;

EID: 84868564569     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12001     Document Type: Article

References (31)

1. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-4. (Pubitemid 46631679)
2. Canfell K, Banks E, Moa AM, Beral V,. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008; 188: 641-4.
3. Parkin DM,. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 2009; 45: 1649-53.
4. Kliewer EV, Demers AA, Nugent ZJ,. A decline in breast-cancer incidence. N Engl J Med 2007; 357: 509-10.
5. Allemand H, Seradour B, Weill A, Ricordeau P,. [Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend]. Bull Cancer 2008; 95: 11-5. (Pubitemid 351265280)
6. Katalinic A, Rawal R,. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008; 107: 427-30. (Pubitemid 351172118)
7. Vankrunkelsven P, Kellen E, Lousbergh D, et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 2009; 118: 425-32.
8. Hemminki E, Kyyronen P, Pukkala E,. Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005. Maturitas 2008; 61: 299-304.
9. Kumle M,. Declining breast cancer incidence and decreased HRT use. Lancet 2008; 372: 608-10.
10. Lambe M, Wigertz A, Holmqvist M, et al. Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 2010; 121: 679-83.
11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33. (Pubitemid 34761611)
12. Beral V,. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27. (Pubitemid 36999703)
13. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350: 1047-59.
14. Bakken K, Alsaker E, Eggen AE, Lund E,. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 2004; 112: 130-4. (Pubitemid 39249500)
15. Hofvind S, Moller B, Thoresen S, Ursin G,. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 2006; 118: 3112-7.
16. Thorat MA,. What caused the decline in US breast cancer incidence? Nat Clin Pract Oncol 2008; 5: 314-5. (Pubitemid 351780948)
17. Jemal A, Ward E, Thun MJ,. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007; 9: R28.
18. Chen CL, Weiss NS, Newcomb P, Barlow W, White E,. Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287: 734-41. (Pubitemid 34250459)
19. Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002; 95: 2455-64. (Pubitemid 35424029)
20. Newcomer LM, Newcomb PA, Potter JD, et al. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 2003; 14: 225-33. (Pubitemid 36649145)
21. Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003.
22. Li CI, Daling JR,. Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 2007; 16: 2773-80. (Pubitemid 351196336)
23. Olsson S, Andersson I, Karlberg I, et al. Implementation of service screening with mammography in Sweden: from pilot study to nationwide programme. J Med Screen 2000; 7: 14-8. (Pubitemid 30305461)
24. Hofvind S, Geller B, Vacek PM, Thoresen S, Skaane P,. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol 2007; 22: 447-55. (Pubitemid 47222954)
25. WHO Collaborating Center (20-8-2009). Available at: http://www.whocc.no/ atcddd/ (accessed September 15, 2009).
26. Li CI, Anderson BO, Daling JR, Moe RE,. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003; 289: 1421-4. (Pubitemid 37430310)
27. JØrgensen KJ, GØtzsche PC,. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009; 339: b2587.
28. The Swedish Cancer Society. (1-10-2008). Available at: http://cancerfonden.se/Global/dokument/press/kampanjer/RB08/frekvens.pdf (accessed June 22, 2009).
29. Skaane P,. Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: updated review. Acta Radiol 2009; 50: 3-14.
30. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009; 45: 1218-31.
31. Barlow L, Westergren K, Holmberg L, Talback M,. The completeness of the Swedish Cancer Register-a sample survey for year 1998. Acta Oncol 2009; 48: 27-33.